




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
O'Brien, P., Han, G., Ganpathy, P., Pitre, S., Zhang, Y., Ryan, J., Sim, P. Y., Harding, S. V., Gray, R., Preedy, V.
R., Sanders, T. A. B., & Corpe, C. P. (2021). Chronic Effects of a High Sucrose Diet on Murine Gastrointestinal
Nutrient Sensor Gene and Protein Expression Levels and Lipid Metabolism. International Journal of Molecular
Sciences, 22(1), 1-26. [137]. https://doi.org/10.3390/ijms22010137
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 25. May. 2021
 International Journal of 
Molecular Sciences
Article
Chronic Effects of a High Sucrose Diet on Murine
Gastrointestinal Nutrient Sensor Gene and Protein Expression
Levels and Lipid Metabolism
Patrick O’Brien 1 , Ge Han 1, Priya Ganpathy 1, Shweta Pitre 1, Yi Zhang 1, John Ryan 1, Pei Ying Sim 1,
Scott V. Harding 2 , Robert Gray 1, Victor R. Preedy 1, Thomas A. B. Sanders 1 and Christopher P. Corpe 1,*


Citation: O’Brien, P.; Han, G.; Ganpathy,
P.; Pitre, S.; Zhang, Y.; Ryan, J.; Sim,
P.Y.; Harding, S.V.; Gray, R.; Preedy, V.R.;
Sanders, T.A.B.; et al. Chronic Effects
of a High Sucrose Diet on Murine
Gastrointestinal Nutrient Sensor Gene
and Protein Expression Levels and Lipid
Metabolism. Int. J. Mol. Sci. 2021, 22,
137. https://dx.doi.org/10.3390/ijms22
010137
Received: 15 November 2020
Accepted: 16 December 2020
Published: 25 December 2020
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional claims
in published maps and institutional
affiliations.
Copyright: © 2020 by the authors. Li-
censee MDPI, Basel, Switzerland. This
article is an open access article distributed
under the terms and conditions of the
Creative Commons Attribution (CC BY)
license (https://creativecommons.org/
licenses/by/4.0/).
1 Nutritional Sciences Division, Faculty of Life Sciences and Medicine, School of Life Courses,
King’s College London, Room 3.114, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, UK;
p.obrien@gmx.net (P.O.); ge.han@kcl.ac.uk (G.H.); priya.ganpathy@gmail.com (P.G.);
shweta.pitre@gmail.com (S.P.); zoeyzhang9496@outlook.com (Y.Z.); j_h_ryan@hotmail.com (J.R.);
spying22@gmail.com (P.Y.S.); robert.gray@kcl.ac.uk (R.G.); victor.preedy@kcl.ac.uk (V.R.P.);
tom.sanders@kcl.ac.uk (T.A.B.S.)
2 Department of Biochemistry, Memorial University, Elizabeth Avenue, St. John’s, NL A1C5S7, Canada;
h32svh@mun.ca
* Correspondence: christopher.corpe@kcl.ac.uk; Tel.: +(44)-2078484269; Fax: +(44)-2078484169
Abstract: The gastrointestinal tract (GIT) plays a key role in regulating nutrient metabolism and
appetite responses. This study aimed to identify changes in the GIT that are important in the
development of diet related obesity and diabetes. GIT samples were obtained from C57BL/6J
male mice chronically fed a control diet or a high sucrose diet (HSD) and analysed for changes
in gene, protein and metabolite levels. In HSD mice, GIT expression levels of fat oxidation genes
were reduced, and increased de novo lipogenesis was evident in ileum. Gene expression levels
of the putative sugar sensor, slc5a4a and slc5a4b, and fat sensor, cd36, were downregulated in the
small intestines of HSD mice. In HSD mice, there was also evidence of bacterial overgrowth and a
lipopolysaccharide activated inflammatory pathway involving inducible nitric oxide synthase (iNOS).
In Caco-2 cells, sucrose significantly increased the expression levels of the nos2, iNOS and nitric oxide
(NO) gas levels. In conclusion, sucrose fed induced obesity/diabetes is associated with changes in
GI macronutrient sensing, appetite regulation and nutrient metabolism and intestinal microflora.
These may be important drivers, and thus therapeutic targets, of diet-related metabolic disease.
Keywords: gastrointestinal; sucrose; nutrient sensors and transporters; gut peptides; nitric oxide
1. Introduction
The prevalence of obesity and associated co-morbidities, such as type 2 diabetes
(T2DM) has substantially increased over the last 4–5 decades [1], and it has been estimated
that between 6% (Japan) and >30% (USA) of the world’s population are now obese [2].
As per the International Diabetes Federation, 463 million adults (20–79 years) were liv-
ing with diabetes in 2019 and the number is expected to rise to 700 million by 2045.
Associated with these metabolic derangements are an increased risk of non-alcoholic
fatty liver disease (NAFLD) hypertension and cardiovascular disease (CVD) leading to
a reduction in quality of life and premature death. Management of these diseases re-
mains a challenge because of the prevailing obesogenic environment in both Western and
developing countries. Increased availability of palatable, energy-dense foods, genetic
predisposition and a sedentary lifestyle are all critical factors; yet the specific mechanisms
of diet-related metabolic disease are not fully understood.
Sucrose is abundant in many processed foods and drinks, including sugar-sweetened
beverages (SSBs). In more recent years, consumption of SSB has dramatically increased
in children and young adults [3,4] contributing to excess calorie intake and obesity while
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providing minimal nutritional value [5]. Systematic reviews and meta-analyses have identi-
fied an association between SSBs intake and the development of obesity and diabetes [6,7],
although there are conflicting findings in the literature [8,9]. Despite these uncertainties,
in 2015, the World Health Organization (WHO) and Scientific Advisory Committee for
Nutrition (SACN) recommended restricting added sugar intake to between 5–10% of
daily calories [10,11]. If added sugars, principally in the form of sucrose, are causal in
the development of metabolic disease, understanding the mechanisms of action could
further support current recommendations and potentially lead to the identification of new
therapeutic targets and treatments.
The gastrointestinal tract (GIT) plays an important role in regulating nutrient
metabolism and energy intake [12]. When food is ingested and digestion begins, taste
cells on the tongue and entero-endocrine cells distributed along the length of the GIT
sense the ingested sugars, fats and proteins and release a number of signalling peptides
(e.g., glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1/(GLP-
1/2) cholecystokinin (CCK) and peptide YY (PPY)) that have both endocrine and paracrine
effects [13]. These peptides influence the function of the GIT (e.g., intestinal secretions,
gastric emptying and nutrient absorption) nutrient metabolism (e.g., insulin secretion) and
food/energy intake. Meta-analysis of human T2DM data suggests minimal differences in
circulating incretins compared to healthy people [14,15]. However, macronutrient sensing
has been shown to be dysfunctional in animal models of obesity and diabetes [16,17].
For example, in rodents fed a high-fat diet, duodenal nutrient-sensing mechanisms are
disrupted, affecting glucose homeostasis [18]. Small intestinal bacterial overgrowth (SIBO)
is also a potential causal factor for metabolic disorders including obesity, diabetes and
NAFLD [19]. In obese patients, the prevalence of SIBO is as high as 41% [20]. The un-
derlying mechanism remains ill-defined, but it has been hypothesized that an imbalance
in available and unavailable carbohydrate levels may promote gut microbiota dysbiosis
and overgrowth [21]. Lipopolysaccharide (LPS) found on the outer membrane of Gram-
negative bacteria also increases nitric oxide (NO) synthesis by pro-inflammatory cytokines
in obesity-induced chronic inflammation [22,23]. NO is a labile lipid soluble gas and
an important signalling molecule, participating in many physiological processes such as
gastrointestinal homeostasis, inflammation and the maintenance of vascular tone [24–26].
Several studies have reported that NO is also a sweet taste-signalling molecule [27] that can
regulate food intake [28]. Understanding the pathways by which dietary changes result in
metabolic disease via alteration in gut microbiota, inflammation and nutrient sensing are
therefore of interest [29].
To identify novel pathways in the development of metabolic disease, we undertook
transcriptomic, proteomic and metabolomic analysis of GIT samples obtained from mice
chronically fed a high sucrose diet for 6 weeks. We also used Caco-2 cells as an in vitro
model of the enterocyte to support our in vivo findings.
2. Results
2.1. Dietary Intake, Anthropometry and Blood Biochemistry Analysis of Control and Sucrose Fed Mice
Control fed mice had free access to water and the control pellet chow, and high sucrose
diet (HSD) fed mice had free access to water, the control pellet chow and light condensed
milk (LCM). As shown in Figure 1a, HSD fed mice almost completely neglected the control
pellet chow. Adult mice normally consume 3–5 g of chow/day (12 g chow/100 g body
weight). Daily average intake of the control fed group was 3.15 ± 0.07 g control diet/day
compared with 4.88 ± 0.06 g of LCM/day for the HSD group (Figure 1b).




Figure 1. Food, macronutrient and energy intake, body weights and blood serum analysis of control fed and high sucrose 
diet (HSD) mice. (a) Daily food intake. (b) Mean daily food intake. (c) Macronutrient intakes calculated from the mean 
daily food intake (pellet and light condensed milk (LCM)) andthe macronutrient composition of control pellet chow and 
LCM (Materials and Methods: Table 3). (d) Daily energy intake. (e) Mean daily energy intake. (f) Body weights. (g) Blood 
serum analysis of glucose, cholesterol, triglycerides, NEFA (all in mmol/L) and Insulin (in ng/mL). Data are presented as 
means ± SE (n = 8). Statistical significance was tested with a Student’s t-test or one-way ANOVA. * p < 0.05, *** p < 0.001, 
ns = not significant. 
Consumption of LCM altered the macronutrient intake of HSD fed mice when com-
pared to controls (Figure 1c). Mice in the HSD group had a significantly higher intake of 
Figure 1. Food, macronutrient and energy intake, body weights and blood serum analysis of control fed and high sucrose
diet (HSD) mice. (a) Daily food intake. (b) Mean daily food intake. (c) Macronutrient intakes calculated from the mean
daily food intake (pellet and light condensed milk (LCM)) andthe macronutrient composition of control pellet chow
and LCM (M terials and Methods: Table 3). (d) Daily e ergy intake. (e) Mean daily energy intake. (f) Body weights.
(g) Blood serum analysi of glucose, cholesterol, triglycerides, NEFA (all in mmol/L) and Insulin (in ng/mL). Da a are
pr sented as means ± SE (n = 8). Statistical significance was tested with a Student’s t-test or one-way ANOVA. * p < 0. 5,
*** p < 0.001, ns = not significant.
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Consumption of LCM altered the macronutrient intake of HSD fed mice when com-
pared to controls (Figure 1c). Mice in the HSD group had a significantly higher intake of
total carbohydrates, mainly sucrose and lactose when compared to the controls. HSD mice
derived 62% of their total caloric intake from sucrose, compared to <11% in the controls
(p < 0.001). Fat consumption at 5% of total daily calories was comparable between control
and HSD mice, but protein intake was significantly lower in HSD mice when compared to
controls (24%, control vs. 14%, HSD). The control diet (AIN93G) contained approximately
4.7% of dietary fibre, and based on an average intake of 3.15 g control pellet/day for
controls and 0.2 g control pellet/day for HSD mice, we estimated that fibre intake for
controls was 0.16 g/day and for HSD mice it was 0.01 g/day.
The increased food intake in HSD fed mice resulted in a higher energy intake over
the course of the study (Figure 1d). Mean daily calorie intake of the control group
was 11.56 ± 0.15 compared with 13.42 ± 0.16 kcal/day (p ≤ 0.001) for the HSD group
(Figure 1e). Body weights were also 22% higher in the HSD fed mice compared to controls
(Figure 1f). At 6 weeks, the average body weights of the control group were 20.6 ± 0.66 g
compared with 25.2 ± 0.42 g for the HSD group.
Biochemical analysis of serum showed that mean fasting glucose levels were sig-
nificantly higher in HSD mice when compared to controls: 5.23 mmol/L for the control
group vs. 11.89 mmol/L for the HSD group (Figure 1g). HSD fed mice were not hyper-
insulinemic compared to controls and blood lipids were not different. Serum cholesterol
approached significance (1.82 vs. 2.08 mmol/L, p = 0.06, HSD vs. control) while triglyc-
erides (0.71 vs. 0.48 mmol/L; p = 0.7) and NEFA (1.50 vs. 0.85 mmol/L; p = 0.31) were
clearly comparable between treatments (HSD vs. control, respectively).
2.2. qPCR Analysis of Small Intestinal Fat Oxidation Genes
Expression levels of fat oxidation genes were also studied in the GIT of control fed
and HSD mice (Figure 2). In control fed mice, Pdk4 gene expression levels were highest in
tongue and jejunum (Figure 2a). Pdk4 gene expression levels were significantly downregu-
lated in all intestinal segments obtained from HSD mice when compared to control fed mice
(Figure 2b). Similarly, jejunal hmgcs2, acot1, acot2, me1 and cyp4a10 gene expression levels
were all significantly downregulated in HSD mice when compared to control fed mice
(Figure 2c–g). Fat oxidation genes were also significantly downregulated in the duode-
num and ileum of HSD mice (data not shown). Array data indicated fat synthesis gene
expression levels were unchanged in small intestinal segments (data not shown).




Figure 2. Fat oxidation gene expression levels in the gastrointestinal tract of mice. (a) Cephalocaudal gene expression of 
pdk4 in control fed mice. (b) pdk4 gene expression in gastrointestinal tract (GIT) segments obtained from mice fed a con-
trol diet vs. HSD. (c–g) hmgcs2, acot1, acot2, me1 and cyp4a10 gene expression levels in the jejunum of control and HSD 
fed mice. Values are normalised against three reference genes; relative expression was performed using the ddCT method 
and expressed relative to the control fed duodenum in panel a and control fed GIT segments in panel b, and the control 
fed jejunum in panels (c–g). Each bar represents the relative mean ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
2.3. Analysis of Intestinal Lipid Metabolites  
Figure 2. Fat oxidation gene expression levels in the gastrointestinal tract of mice. (a) Cephalocaudal gene expression of
pdk4 in control fed mice. (b) pdk4 gene expression in gastrointestinal tract (GIT) segments obtained from mice fed a control
diet vs. HSD. (c–g) hmgcs2, acot1, acot2, me1 and cyp4a10 gene expression levels in the jejunum of control and HSD fed
mice. Values are normalised against three ref rence genes; r lative expr ssion was performed using the ddCT method an
expr ssed relative o the contr l fed duo enum in pa el a and contr l fed GIT segm nts i pa el b, and the contr l fed
jejunum in panels (c–g). Each bar represents the relative mean ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant.
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2.3. Analysis of Intestinal Lipid Metabolites
Analysis of the fatty acid composition of all intestinal tissues was undertaken; however,
we only found significant differences in the ileum (Figure 3a). The HSD treatment resulted
in higher levels of 16:0, 16:1 and 18:1n-9 and lower levels of 14:0, 18:0, 18:2n-6, 20:3n-6 and
20:4n-3 in ileum compared to controls. The 16:0/18:2n-6 ratio, serving as an indicator of de novo
lipogenesis (DNL) was also increased in ileal samples obtained from rodents fed the HSD diet
(Figure 3b). The 18:1n-9/18:0 ratio, serving as an indicator for stearoyl-CoA desaturase (SCD)
activity, was also studied using the data from lipid analysis (Figure 3c). The 18:1n-9/18:0
ratio in ileum was found to be significantly higher in HSD fed mice compared to controls.
Liquid chromatography–mass spectrometry was performed to quantify oleoylethanolamide
(OEA) and palmitoylethanolamide (PEA), each derived from 18:1n-9 and 16:0, respectively.
Similar to the SCD desaturase activity, the OEA:PEA ratio was significantly higher in the HSD
group, but only in ileum (Figure 3d).
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2.4. Validation of Microarray Data Obtained from the Small Intestines of Control and Sucrose Fed Mice
From the gene array data, taste- and nutrient-sensing genes including fat-, umami-,
sour- and bitter-taste genes, as well as downstream signalling molecules, such as Gustducin,
were manually extracted and fold changes reported (Table 1). Only minor changes in in-
testinal nutrient sensor gene expression levels were detected; however, the gene expression
levels for the Na+ dependent sugar sensor SGLT3 (slc5a4a and slc5a4b) and the fat sensor
CD36 (cd36) were downregulated by as much as 4-fold in the duodenum and jejunum of
HSD fed mice.
Table 1. Fold changes of regulated nutrient-sensor genes in the small intestine of HSD-fed mice
compared with control fed mice. RNA was pooled from 8 mice per control and HSD group and
analysed on an Affymetrix microarray chip.
Protein Gene Name Fold Change Ctrl vs. HSD
Duo Jej Ile
Sweet T1R2 tas1r2 1.15 −1.03 1.12
T1R3 tas1r3 1.13 1.07 −1.05
SGLT3a slc5a4a −2.61 −1.73 1.19
SGLT3b slc5a4b −4.23 −3.0 −1.13
Fat CD36/FAT cd36 −4.62 −3.12 −1.41
FFAR2 ffar2 1.02 1.04 1.09
GPR120 gpr120 −1.10 −1.21 −1.13
Umami mGluR4 grm4 −1.03 −1.13 −1.01
T1R1 tas1r1 1.11 −1.07 −1.15
Sour TRPP3 pkd2l1 1.15 1.00 −1.13
ENaCα scnn1a −1.09 −1.15 −1.06
ENaCβ scnn1b 1.00 −1.31 −1.07
ENaCγ scnn1c NA NA NA
Bitter T2R102–T2R143 tas2r102–tas2r143 −1.43–1.33 −1.59–1.22 −1.27–1.06
Signalling αGustducin gnat3 1.28 1.31 1.29
αTransducing gnat1 1.19 −1.44 −1.74
TRPM5 trpm5 1.66 1.20 1.14
Phospholipaseβ2 plcb2 1.52 1.18 −1.04
To validate the array data, qPCR analysis of sugar sensor genes expression levels
was undertaken in tongue, stomach, duodenum, jejunum and ileum tissues obtained from
control and HSD fed mice (Figure 4). Consistent with array data, Tas1r2 was unchanged in
control and HSD fed mice in all tissues (Figure 4a). Tas1r3 was also unchanged in control
and HSD fed mice along the length of the GIT, although a modest (28%) downregula-
tion in jejunum (p < 0.05) and ileum (p = 0.08) was noted in HSD fed mice (Figure 4b).
SGLT3a (slc5a4a) and SGLT3b (slc5a4b) were both downregulated in the duodenum and
jejunum (Figure 4c,d) as was cd36 (Figure 4e), although significance was only reached in
the jejunal samples.
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relative mean ± SE. * p < 0.05, ** p < 0.01, ns = not significant.
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2.5. Western Blot Analysis of Small Intestinal Sugar Sensors and Transporters
To assess changes in GLUT2 and SGLT3 protein expression levels, we undertook West-
ern blot analysis of duodenal, jejunal and ileal proteins harvested from control and HSD
fed mice. Western blot analysis showed no change in SGLT3 (Figure 5a–c) in duodenum,
jejunum and ileum obtained from control and HSD mice.
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Figure 5. GLUT2 and SGLT3 protein expression levels in the small intestinal segments of mice. Whole (a) duodenum,
(b) jejunum and (c) ileum were dissected from C57BL/6 mice fed a control diet or HSD (n = 8 per group) and proteins
extracted for Western blots of β-Actin, GLUT2 and SGLT3. Representative blots are shown. Blots were quantified and
normalised against β-Actin and are expressed relative to the control group. Each bar represents the relative mean ± SE.
** p < 0.01, ns = not significant.
GLUT2 protein expression levels were also unchanged in duodenum and jejunum
(Figure 5a,b), but significantly increased 1.5-fold in ileum (p < 0.01) (Figure 5c), consistent
with the pattern of GLUT2 gene expression changes detected in array data analysis of
pooled RNA samples. In arrays, sucrase- Isomaltose and SGLT1 gene expression levels
were also unchanged in all small intestinal regions, whereas GLUT5 was downregulated
almost 2-fold but only in the ileum (data not shown).
2.6. qPCR Analysis of Gut Peptide Gene Expression Levels
Gene expression levels of ghrelin (ghrl), CCK (cck) and preproglucagon (gcg) in in-
testinal segments of control and HSD fed mice were also analysed by qPCR (Figure 6).
Ghrl showed a 4-fold induction in the stomach (Figure 6a) but did not reach statistical
significance (p = 0.13). Cck expression was significantly upregulated by 65% in the jejunum
of HSD mice when compared to controls (Figure 6b) but not in duodenum and ileum.
Expression of gcg, the gene responsible for the synthesis of GLP-1 and -2, was increased in
the ileum by 65% (p = 0.055) (Figure 6c) and decreased in the duodenum by 50% (p = 0.11)
and was unchanged in jejunum. Array ata indicated that gen expression levels for
ghrelin (duo: −1.52, jej: 1.03, ile: 1.21) and gip (duo: −1.20, jej: −1.16, ile: 1.21) were
minimally changed in all thre small intestinal segments obtained from control and HSD
fed mice (data not shown).
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opolysaccharide (LPS) induced inflammation in the small intestines of HSD fed mice (Fig-
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(MIF), which promotes increased gene expression of myeloid differentiation protein-2 
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Figure 6. Gut peptide gene expression in the gastrointestinal tract of mice. Whole stomach, duode-
num, jejunum and ileum were dissected from C57BL/6 mice fed the HSD or the control diet. RNA
was extracted for subsequent quantitative PCR of the gut peptides (a) ghrl (Ghrelin), (b) cck (CCK)
and (c) gcg (Preproglucagon). Values are normalised against three reference genes; relative expression
was performed using the ddCT method and expressed relative to the control diet. Each bar represents
the relative mean ± SE. * p < 0.05, ns = not significant.
2.7. Identification of an LPS Mediated Inflammatory Pathway by GeneGo Metacore Pathway
Analysis of Microarray Data and Validation by qPCR
Pathway analysis of our array data using GeneGo MetaCore software identified
lipopolysaccharide (LPS) induced inflammation in the small intestines of HSD fed mice
(Figure 7). LPS triggers an inflammatory pathway modulated by macrophage inhibitory
factor (MIF), which promotes increased gene expression of myeloid differentiation protein-
2 (MD-2), inhibitory factor KB (I-kb), inducible NOS and interleukin-1, summarized in
Table 2.
To validate the array data, qPCR analysis of inflammatory pathway genes was under-
taken. LY96 was upregulated 2–2.5-fold in jejunum and ileum (Figure 8a), and NFKb was
upregulated 2-fold in duodenum (Figure 8b) but did not reach significance. IL-1 was up-
regulated 3-fold in jejunum (p < 0.05) (Figure 8c). qPCR analysis of NOS2 along the length
of the GIT of control fed mice showed the highest expression levels in the distal regions of
the small intestine (Figure 8d). Consistent with the array data and pathway analysis, qPCR
studies showed that NOS2 gene expression levels in HSD mice were upregulated in the
duodenum and jejunum (Figure 8e) as well as all other intestinal tissues when compared
to control fed mice. NOS2 was significantly upregulated by 7-fold in the tongue (p < 0.001),
34-fold in the duodenum (p < 0.05), 6-fold in the jejunum (p < 0.05) and 4-fold in the ileum
(p = 0.055). In the stomach, NOS2 was upregulated 2-fold in HSD mice but did not reach
statistical significance.
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expression in jejunum and ileum. (b) NFKβ1 in duodenum. (c) IL-1β in jejunum. (d) Cephalo-
caudal expression of NOS2 in control fed mice. (e) NOS2 expression in all GIT segments obtained 
from mice fed a control diet vs. HSD. Values are normalised against three reference genes; relative 
expression was performed using the ddCT method and expressed relative to duodenum for the 
cephalocaudal figures and the control diet for all other figures. Each bar represents the relative 
mean ± SE. * p < 0.05, *** p < 0.001, ns = not significant. 
2.8. qPCR of the Small Intestinal Microflora 
To assess changes in the microbial population along the length of the GIT in control 
and HSD mice, qPCR analysis of 16S rRNA (a bacterial marker gene) was undertaken 
(Figure 9). In control fed mice, tongue, stomach and ileum had the highest 16S rRNA ex-
pression levels and duodenum and jejunum the lowest (Figure 9a). Following exposure to 
HSD, there was a 4–12-fold upregulation in 16s rRNA expression levels in the stomach (p 
Figure 8. LPS-induced inflammation gene expression levels in the gastrointestinal tractof mice.
Tongue, stomach, duodenum, jejunum and ileum were dissected from C57BL/6 mice fed either the
control diet (n = 8) or HSD (n = 8) and RNA extracted for subsequent quantitative PCR. (a) LY96
expression in jejunum and ileum. (b) NFKβ1 in duodenum. (c) IL-1β in jejunum. (d) Cephalocaudal
expression of NOS2 in control fed mice. (e) NOS2 expression in all GIT segments obtained from mice
fed a control diet vs. HSD. Values are normalised against three reference genes; relative expression
was performed using the ddCT method and expressed relative to duodenum for the cephalocaudal
figures and the control diet for all other figures. Each bar represents the relative mean ± SE. * p < 0.05,
*** p < 0.001, ns = not significant.
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2.8. qPCR of the Small Intestinal Microflora
To assess changes in the microbial population along the length of the GIT in control
and HSD mice, qPCR analysis of 16S rRNA (a bacterial marker gene) was undertaken
(Figure 9). In control fed mice, tongue, stomach and ileum had the highest 16S rRNA
expression levels and duodenum and jejunum the lowest (Figure 9a). Following exposure
to HSD, there was a 4–12-fold upregulation in 16s rRNA expression levels in the stomach
(p < 0.05), duodenum and ileum (Figure 9b). No significant fold changes in 16S rRNA gene
expression were observed in the tongue and jejunum (p > 0.05).
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using the ddCT method and expressed relative to the du denum in panel a and control fed GIT segments in panel b. Results
are expressed as means ± SE. HSD, high sucrose diets. * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant.
2.9. The Effects of Sugars and LPS on Nitric Oxide Production In Vitro
To study the regulation of gastrointestinal NO by sugars and microbiota, we exposed
Caco-2 cells (an in vitro model of the human enterocyte) to glucose, sucrose and LPS for
48 h and measured NOS2 gene and iNOS protein expression levels and NO gas secretion
(Figure 10). When compared to 5 mM glucose, NOS2 mRNA levels were upregulated
by 25 mM sucrose and 100 µg/mL LPS with 25 mM sucrose (p < 0.05) (Figure 10a) but
not by 25 mM glucose. iNOS protein is a 1135 amino acid protein with a predicted Mw
of 130 kD [30]. However, a single 50 kD iNOS protein was detected when Caco-2 cell
samples were Western blotted (Figure 10b). Furthermore, when compared to the glucose
control, a 48 h exposure to 25 mM sucrose resulted in a significant increase in iNOS protein
expression levels, whereas protein expression levels were unresponsive to 25 mM glucose
or 1 µg/mL LPS with 25 mM sucrose. When compared to 5 mM glucose control, NO gas
production was significantly increased after Caco-2 cells were exposed to 25 mM sucros
(p = 0.004), and 100 µg/mL LPS with 25 mM sucrose (p = 0.001) for 48 h, but not following
exposure to 25mM glucose (Figure 10c).
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Figure 10. Nitric oxide studies in Caco-2 cells. Caco-2 cells were exposed to sugars and LPS for 48 h (n = 4 for each
treatment). Total mRNA and proteins were then extracted and iNOS gene and protein expression measured by qPCR and
Western blotting, respectively. Supernatants were also collected for NO gas analysis. (a) NOS2 gene expression levels
normalized against β-actin. (b) iNOS protein expression levels. Protein density ratio of iNOS expression with β-actin
normalization using Image-J software. (c) NO gas concentrations in the supernatants of Cac -2 cells. Values are presented
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3. Discussion
The aim of this study was to identify changes in GIT function in mice chronically fed a
hig sucrose diet to induce obesity and diabetes. In the present study, C57BL/6 mice were
given free access to a control pellet diet containing 2% corn oil and sweetened light con-
densed milk (LCM) supplemented with 1% corn oil. Animals consumed significantly higher
amounts (p < 0.001) of LCM when compared to the control pellet diet, resulting in a switch
from dietary starch to added sugars (LCM, 45% sucrose/ 10% lactose). Associated with this
diet ry switch was an increase in energy intake (hyperphagia) (p < 0.001) most likely riven
by increased palatability of the LCM diet via stimulation of dopamine in the mesolimbic
system and the hypothalamic reward centres [31,32]. The observed hyperphagia is unlikely
to be responsible for the observed weight gain and metabolic disturbances, since pair fed
studies using HSD and control fed rodents also reported weight gain, diabetes and hepatic
steatosis [33]. Consisten wit other reports, th HSD fed mic were also hyperglycaemic,
but not hyperinsulinemic, suggesting the animal was diabetic due to insulin resistance and
pancreatic beta cell exhaustion [34–36].
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When dietary sucrose is ingested, it is split into free glucose and fructose in the
small intestine by sucrase isomaltose (SI) expressed on the apical membrane of entero-
cytes. The free glucose and fructose is then transported across the gut via SGLT1 and
GLUT5 expressed on the apical membrane and GLUT2 expressed on the basolateral mem-
brane [37]. Approximately 25% of the glucose load that enters the portal vein is extracted
by the liver, whereas almost all of the fructose is extracted by the liver during the first
pass [38]. In addition, because fructose metabolism in the liver bypasses key rate limit-
ing glycolytic enzymes (e.g., phosphofructokinase (PFK)), carbons derived from fructose
that are in excess of energy needs of the liver are converted into glucose and lactate via
gluconeogenesis, and fatty acids via DNL. Increased DNL involves not only enhanced fat
synthesis but also suppression of fat oxidation [39]. Triglycerides produced via DNL are
either stored in the liver or exported into blood raising circulating triglyceride levels [40].
The idea that the liver is the principal site of fructose metabolism has, however, recently
been questioned [41]. In mice studies, when fructose loads are low (0.25–0.5 g/kg body
weight), the gut converts the sugar into glucose and organic acids, such as fatty acids, uric
acid, glycerate and glutamate. When loads of fructose are high (>1 g/kg body weight),
the capacity of the gut to metabolise fructose is exceeded and the free fructose passes to
the liver where it is then metabolised as described above. In addition, in Chinese ham-
sters fed a high fructose diet (60% w/w) for three weeks, lipid synthesis was enhanced in
enterocytes, resulting in increased synthesis of apoB48 and release of intestinal-derived
chylomicrons, likely via activation of the carbohydrate response element binding protein
(ChREBP) and the facilitative fructose transporter, GLUT5 [42]. In small intestinal segments
of HSD mice, fatty acid oxidation (FAO) genes were significantly decreased, whereas fatty
acid synthesis genes were unchanged (array data not shown) when compared to controls.
Although the decrease in FAO gene expression suggests the balance in lipid metabolism
in the gut has shifted toward lipid synthesis, evidence of increased DNL was detected
only in ileal samples of HSD mice. In addition, although rodent studies have shown
that the intestinal contribution to circulating triglycerides ranges between 10 to 40% of
total plasma triglyceride [43], the increased ileal DNL in HSD mice was not sufficient to
raise blood triglycerides. The liver is the principle tissue responsible for fructose induced
hypertriglyceridemia, and long-term exposure to dietary sucrose (and fructose) results in
the development of fatty livers (NAFLD) which can progress to non-alcoholic steatohep-
atitis (NASH) [44]. NAFLD/NASH is associated with a decrease in the secretion of TGs,
synthesis of apolipoprotein B-100 and import and export of VLDLs [45], which may also
explain why circulating triglycerides in HSD mice were no different to controls.
The OEA:PEA ratio was increased in HSD mice ileum. OEA is a fatty acid ethanolamine
of oleic acid that is synthesized by proximal enterocytes upon feeding [46] and induces
satiety via activation of the transcriptional factor, PPAR-alpha, which suppresses iNOS gene
expression [47,48]. iNOS gene expression levels were, however, increased in all regions of
the GIT, including the ileum, suggesting the satiating effect of ileal OEA was overwhelmed
by other metabolic events discussed below.
Distributed along the length of the GIT are numerous nutrient (energy) sensing cells
(e.g., taste cells, X/A cells, K, I and L cells) that release a number of signalling peptides
(e.g., ghrelin, GIP, CCK and GLP1) in response to the ingestion of fats, carbohydrates and
proteins [49,50]. The signalling peptides have both paracrine and endocrine effects, influ-
encing taste preference, gastric emptying, nutrient absorption, insulin secretion and food
intake. The molecular mechanisms by which macronutrients are sensed by gut have largely
been established (e.g., the sweet taste receptors: T1r2/3, SGLT1 and SGLT3; fat sensors:
CD36 and GPR120; and amino acid sensors, PEPT1 and LAT1) [51–53]. Studies have also
shown that when the luminal macronutrient load changes, there are alterations in nutrient
sensor gene expression levels and nutrient perception [54,55]. The HSD mice showed
a clear preference for the sucrose sweetened milk in our study; however, tas1r2/3 gene
expression levels along the length of the GIT tract were unchanged compared to controls,
suggesting that changes in sweet taste preference are not mediated via alterations in tas1r2/3
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receptor gene expression levels. Alternative sugar sensor mechanisms exist on the tongue,
such as amylase, SI and SGLT1 [56], and we cannot rule out changes in their expression
levels altering taste sensitivity. In the duodenum and jejunum of HSD fed mice, we did
detect a downregulation in the gene expression levels of the putative sugar sensor SGLT3,
namely, slc5a4a and slc5a4b. SGLT3 is expressed in cholinergic neurones in the submucosal
and myenteric plexus and in portal vein, and is thought to be a sugar sensor that activates
vagal afferents [52]. Because SGLT3 activity is sensitive to pH, SGLT3 may also play a role
in regulating gastric emptying. Because SGLT3 protein expression was unchanged in HSD
mice compared to controls, it is difficult to conclude what the physiologic importance of
altered SGLT3 gene expression levels are. Discordance in gastro-intestinal SGLT3 gene and
protein expression levels has previously been detected [57] suggesting post-translational
modification. We speculate that increased levels of dietary simple sugars may stabilize
the protein product, and thus gene transcriptional activity required to maintain protein
expression levels are reduced. Taste sensitivity to fat is also influenced by the levels of
dietary fat, that is, low fat diets result in increased sensitivity to fat and vice versa [58].
Furthermore, sensitivity appears to be mediated by alterations in the expression levels
of the fat sensor, CD36 [59,60]. In the HSD mouse, cd36 gene expression levels were also
significantly downregulated in duodenal and jejunal samples, suggesting that sensitivity
to dietary fat could be lower in the HSD mice. CD36 plays an important role in upreg-
ulating fat oxidation, and blocking CD36 inhibits fatty acid oxidation and promotes fat
accumulation [61]. Although fat intake levels in the control and HSD diet were unchanged,
these data suggest a novel pathway by which added sugars may result in overconsumption,
that is, via a reduced ability to sense and respond to dietary fat. Future studies in rodents
and people could test this hypothesis.
Because HSD mice were hyperphagic we also assessed the gene expression levels of
the anorexigenic/ orexigenic and incretin hormones in our intestinal samples. In HSD
mice, the gene expression levels of the hunger hormone, ghrl (Ghrelin), were upregulated
four-fold in stomach, although it did not reach statistical significance. The detected increase
in ghrelin gene expression levels might be due to an increase in the number of ghrelin
positive X/A cells, as this has been observed in the stomachs of obese mice fed a high fat
diet [62]. Together, these data suggest that the increase in the number of ghrelin producing
cells in obesity might be due to a systemic signal altering the cellular repertoire of the
stomach, rather than alterations in luminal macronutrient levels. In humans who are obese
and have T2DM, there is evidence of ghrelin resistance, and ghrelin secretion and levels in
blood are in fact decreased [63,64]. The increase in ghrelin gene expression (via increased
ghrelin positive cell number) may, therefore, be an attempt by the stomach to compensate
for a reduction in ghrelin secretory capacity [62].
In HSD mice, cck gene expression levels were upregulated only in the jejunum. CCK is
a satiety hormone synthesised in I cells that is released in response to dietary fatty acid and
amino acid intake inhibiting gastric emptying via activation of vagal afferents [65]. Elevations
in CCK levels in the small intestines of obese humans have been detected, and it has been
suggested that this may be an adaptative response to CCK-receptor resistance [66,67]. CCK is
known to suppress carbohydrate intake and reduce food intake via the CCK-A receptor [68].
Our finding suggests that the gut compensates for reduced CCK signalling by increasing cck
gene expression, either via changes in transcription or I cell number.
In HSD mice, gene expression levels of gcg, the precursor of GLP1/2, were down-
regulated in duodenum and upregulated in ileum, although the fold changes did not
quite reach statistical significance. GCG is expressed in L cells, and these data may reflect
an alteration in either gene transcription or L cell density along the length of the GIT
in HSD mice, which has previously been observed in the large intestines of high fat fed
models of obesity and in diabetes, although not in the small intestine [69]. In diabetes,
GLP1 secretion is only mildly attenuated [70]. The impairment in GLP1 secretion may
occur primarily in the duodenum and be responsible for the proposed anti-incretin effect
detected in morbidly obese individuals with T2DM [71]. Our data suggest that this could
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be partially compensated for by increased gcg expression and GLP1 secretory capacity in
the distal gut.
To further investigate changes in GIT gene expression levels, GeneGo MetaCore
pathway analysis of small intestinal segments obtained from control and HSD mice was
undertaken which identified a LPS activated inflammatory pathway involving iNOS,
which we validated by qPCR. LPS is found in the outer membrane of Gram-negative
bacteria, and previous studies have shown the Gram-negative microbiota is elevated in
obese patients when compared to healthy people [72]. Small intestinal bacterial overgrowth
(SIBO) is characterized by excessive growth of bacteria in the small intestine, and is cited
as a potential causal factor for NAFLD diseases and metabolic disorders including obesity
and diabetes [19]. SIBO was observed in 41% of obese patients [73]. Moreover, it was
found that 75% of diabetic patients with SIBO showed improved GIT symptoms after
treatment with antibiotics [74]. The underlying mechanisms linking SIBO and metabolic
disorders remain ill-defined, but it has been hypothesized that alterations in available
and unavailable dietary carbohydrate levels may promote gut microbiota dysbiosis and
overgrowth [21]. Indeed, in our HSD mouse, sucrose replaced starch as the principle
ingested available carbohydrate, and fibre intakes were dramatically reduced in HSD mice
because of the switch from the control pellet to LCM. This raises the possibility that in a
low fibre environment, the intestinal microbiota migrate out of the large intestine in search
of energy providing substrates, and in the proximal regions of the gut, they may compete
with the energy sensor cells of the gut for substrates, potentially leading to disturbances
in nutrient sensing, peptide secretion, metabolism and even behaviour [75]. In addition,
when LPS is synthesized by intestinal bacteria, it enters the host bloodstream and promotes
the upregulation of pro-inflammatory cytokine expression [76,77]. In HSD mice, there is
also evidence that LPS upregulates several genes involved in intestinal inflammation.
LPS and inflammatory molecules such as Il-1β downregulate GLUT5 [78,79], which might
explain the reduction in GLUT5 gene expression in HSD ileum (array data not shown).
The detected change in iNOS is also associated with the pathogenesis of metabolic diseases.
Several studies have shown NO to be an important GIT signalling molecule and that
inhibition of NOS by N omega-Nitro-L-arginine methyl ester hydrochloride (L-NAME)
suppresses appetite and decreases intake of a palatable milk diet [80,81].
In HSD mice, 16sRNA gene levels were increased in all regions of the GIT, except for
the jejunum. Therefore, the detected changes in jejunal gene expression levels, including
the upregulation in nos2, could not have been driven by changes in bacterial load/LPS.
Indeed, in our Caco-2 cell experiments, we showed that sucrose can also cause an increase
in nos2 gene, iNOS protein and NO gas production. The genes responsible for the sweet
taste receptor homodimer T1R3 and the putative sugar sensor SGLT3 are expressed in
Caco-2 cells [82]; however, it is unlikely that sucrose’s effect on iNOS is mediated by
the sugar sensors, simply because T1R3 responds only to very high levels of sucrose
(>300–500 mM) [83] and depolarisation of the cell membranes occurs only when glucose and
its analogs bind to SGLT3 [52]. When dietary sucrose is ingested, it can be partially broken
down into free glucose and fructose by SI expressed on the taste cells of tongue and in small
intestine and by the acid present in the stomach. SI is also expressed in Caco-2 cells [84].
Glucose had no effect on NO in Caco-2 cells, suggesting fructose, along with LPS mediated
inflammation, is most likely responsible for the changes in NO. In support, in fructose fed
rodents, the levels of blood NO are increased [85] and iNOS gene, and protein expression
levels are increased in the aortas of high fructose corn syrup (HFCS) fed rodents [86],
although endothelial eNOS is decreased resulting in dysregulation of vascular tone and
hypertension [87].
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The molecular mechanisms by which dietary sucrose ( and fructose) results in the
detected change in gut gene expression levels remain unclear. From our array data, we did
not find any changes in the expression levels of transcriptional factors involved in reg-
ulating sugar transport and metabolism, namely, ChREBP [88] thioredoxin interacting
protein (TxNip) [89] or Liver X receptor-α (LXR-α) [90]. Increased intracellular fructose
leads to elevations in uric acid levels which might be important [39]. Uric acid can acti-
vate NADPH oxidase, leading to oxidative stress and the activation of the transcription
factor, NFkB, which in turn can lead to increased nos2 gene transcription. Mitochondrial
oxidative stress can also cause a reduction in aconitase-2 activity [91] and enoyl CoA
hydratase-1, a rate-limiting enzyme in β-fatty acid oxidation [92]. Uric acid is also known
to increase AMP Deaminase activity which blocks fat oxidation by inhibiting the energy
sensor AMP-activated protein kinase [93]. Future studies will, therefore, involve study-
ing the regulation of intestinal nutrient sensors, SGLT3 and CD36, by uric acid and its
downstream signalling molecules.
In summary, dietary sucrose induced obesity/diabetes in mice is associated with
alterations in numerous gastrointestinal genes involved in macronutrient sensing, appetite
regulation, nutrient metabolism and intestinal microflora. Causality, however, remains an
unanswered question. To better understand the importance of the changes in microflora and
iNOS in intestinal nutrient sensing and the HSD phenotype, in the future, a more detailed
characterization of the microflora, probiotic and prebiotic interventions and treatment with
the nitric oxide synthase inhibitor (L-NG-nitro-arginine methyl ester) will be undertaken.
These studies will identify viable therapeutic targets and strategies for the management of
diet related metabolic disease.
4. Materials and Methods
4.1. Laboratory Animals and Study Protocol
Sixteen C57BL/6J juvenile male mice (28 days of age) were obtained from Charles
River, UK, and were randomly assigned to two groups (n = 8 each): a control group or a
high-sucrose diet (HSD) group. Mice weighing 16.5 ± 0.59 g and 16.5 ± 0.39 g were placed
in the control group and the HSD group, respectively. Mice were individually housed in
cages with wood-chip bedding (Utemp1284 cages, Techniplast, UK; Aspen-wood chips,
B and K Ltd.) under controlled temperature (20–22 ◦C) and humidity conditions (45–65%)
with a 12 h light/dark cycle.
In pilot feeding studies, HSD fed mice consumed large amounts of LCM and very
little of the control chow diet resulting in changes in sugar as well as fat intakes. In order
to ensure fat consumption (specifically linoleic acid) was similar between control and HSD
mice, 1% corn oil was added to LCM and 2% corn oil to the control chow diet. Mice were
acclimatised for one week with free access to the control diet (2% corn oil pellets) and
water. After the acclimatisation period, the control mice were continued on the control diet,
and the HSD mice were given free access to light condensed milk (LCM) (Carnation milk,
Nestlé, UK) containing 1% corn oil in addition to the control diet (AIN93G) for a period of
six weeks (Table 3 for diet composition).
Int. J. Mol. Sci. 2021, 22, 137 19 of 26
Table 3. Macronutrient composition of control pellet chow and LCM.
2% Corn Oil Chow LCM + 1% Corn Oil
g/100 g kcal/100 g g/100 g kcal/100 g
Total carbohydrate 68 255 59.5 223.1
Starch 58 217.5 0 0
Sucrose 10 37.5 47.3 177.4
Lactose 0 0 12.2 45.7
Fat 2 18 1.2 10.8
Protein 20 80 9.3 37.2
Total 100 353 100 271.1
Throughout the intervention, body weights, chow intake and LCM consumption
were recorded daily. These data were used to calculate macronutrient and energy intake.
After the six-week dietary intervention, all animals were fasted overnight to minimise
the variation in the time between the last food intake and blood and tissue collection.
All animals were euthanised by cervical dislocation whilst under halothane anaesthesia.
Tissues were dissected into tubes and immediately snap-frozen in liquid nitrogen for further
RNA and protein extraction. All procedures were carried out according to the project license
guidelines under the UK Home Office Animals Scientific Procedures Act, 1986.
4.2. Serum Analysis
Blood samples were collected via decapitation and left to drain into a 2 mL sterile tube
and whole blood was processed to obtain serum. Serum glucose, insulin, cholesterol and
triglycerides were analysed using Siemens Healthcare Diagnostics Ltd. kits, following the
manufacturer’s instructions at KingsPath King’s College London Hospital. Non-esterified
fatty acids (NEFA) were analysed using a using a calorimetric assay (Wako Diagnostics,
Richmond, VA, USA).
4.3. Cell Culture
Caco-2 cells were grown in 25 mM D-Glucose Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum, 50 units penicillin and 50 µg streptomycin,
0.1 mM MEM non-essential amino acids and additional 2 mM L-glutamine (Gibco).
Cells were maintained in T25 flasks, split 1:20 once a week at ~80% confluence and seeded
for experimentation at a density of 10,000 cells/cm2 in 24 multi-well dishes. Medium was
changed every other day until confluent, and daily after reaching confluence. For experi-
ments, cell passages between 38 and 50 were used.
Confluent cell monolayers were washed twice with 1X phosphate buffered saline
(PBS, G-Biosciences, St. Louis, MO, USA). Cells were then exposed to different concen-
trations of sugars and LPS including 5 mM glucose, 25 mM glucose, 25 mM sucrose
(Sigma-Aldrich, Gillingham, UK), and 100 µg/mL LPS with 25 mM sucrose, separately.
LPS was isolated from Escherichia coli (EMD Millipore Corporation, Temecula, CA, USA).
After sugar and LPS exposure for 48 h, cells were harvested for RNA and protein extraction,
and supernatants collected.
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4.4. RNA Extraction
Intestinal tissues were incubated overnight in RNAlater®-ICE solution (Life Technolo-
gies, Carlsbad, CA, USA) at −80 ◦C, and 15 mg of the tissue was homogenized in Qiazol
lysis reagent (Qiagen) in the Qiagen TissueLyser for 3 × 30 s at 30 Hz, and RNA extracted
using a RNeasy Lipid Tissue Mini Procedure (Qiagen, The Netherlands), following the
manufacturer’s protocol.
Confluent Caco-2 cells were washed with ice-cold PBS and lysed with cold TRIzol®
reagent. Chloroform and RNase-free water were added to the cell lysate, rigorously
vortexed for 15 s and incubated for 10 mins at room temperature. Samples were then
centrifuged at 13,000 RPM at 4 ◦C for 10 mins, and the aqueous phase was removed and
mixed with ice-cold isopropanol and incubated at−20 ◦C for 30 min. RNA was precipitated
by centrifugation at 13,000 RPM at 4◦C for 30 min. The resulting pellet was washed twice in
75% v/v ethanol and centrifuged for 5 min at 13,000 RPM at 4 ◦C. The RNA pellet was then
re-suspended in RNAse-free water, and RNA concentration (ng/µL) and purity (260/280)
were measured (Nanodrop 2000).
4.5. Microarray Analysis
An amount of 400 ng of RNA was pooled together from duodenal, jejunal and ileal
samples from control and HSD fed mice and RNA integrity confirmed on an Agilent
Bioanalyzer chip. RNA was then labelled with a GeneChip® 3′ IVT Express Kit (Affymetrix,
Santa Clara, CA, USA) and analysed using the GeneChip MouseGenome 430A 2.0 Array
following the manufacturer’s instructions. Data were analysed using the GeneGo software
(MetaCore™, version 6.19 build 65960—Thomson Reuters).
4.6. Quantitative Polymerase Chain Reaction (qPCR)
An amount of 1 µg of RNA obtained for intestinal tissue segments or Caco-2 cells
was reverse transcribed with a high capacity RNA-to-cDNA kit (Applied Biosystems,
Waltham, MA, USA) according to the manufacturer’s protocol in a PTC-200 thermal cycler.
The resulting cDNA was diluted 1:10 in water, and PCR performed using 10 ng cDNA
and a primer concentration of 900 nM with FastStart Universal Probe Master (Rox) (Roche,
Switzerland) mastermix. PCR conditions: using AB 7000 qPCR cycler (Applied Biosystems,
USA), 10 min at 95 ◦C for polymerase activation, 40 cycles of 95 ◦C annealing for 15 s and
1 min at 60 ◦C for amplification. Primers (Table 4) were designed using Roche’s online
ProbeFinder Software, v. 2.50. The mouse genome was selected to design PCR assays over
exon–exon borders for transcriptome specificity. All primers were obtained from Integrated
DNA Technologies (Leuven, Belgium) and reconstituted with ultrapure water to a stock
concentration of 10 µM.
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Table 4. Primer sequences used in real-time RT-PCR.
























An amount of 15 mg of intestinal tissue was dissected on ice and homogenised in ice
cold protein extraction buffer (1 mM fresh DTT, 50 mM Tris-HCl pH 7.4, 250 mM mannitol,
100 mM NaCl, 1mM EDTA, 1 mM EGTA, 10% glycerol) containing 1x protease-inhibitor
cocktail (Sigma-Aldrich P8340, Dorset, UK) using a Qiagen TissueLyser for 2 × 60 s at
30 Hz. Samples were then incubated on a rotating spinner for 30 min at 4 ◦C and then
centrifuged at 13,000 RPM for 10 min at 4 ◦C. The protein-containing supernatant was
transferred into a new tube. Protein content was quantified using a Pierce™ BCA Protein
assay kit.
Caco-2 cell proteins were collected after being washed with 1X cold PBS twice and
lysed with RIPA buffer (1 mmol/L Halt Protease Inhibitor Single and 5 mmol/L EDTA).
The concentration of each sample was determined using Bradford Protein Assay kit (Ther-
moFisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocols.
4.8. Western Blotting
Protein lysates were made up at a final concentration of 5 µg/µL, including 4x
NuPAGE® LDS sample buffer (Life Technologies) and 10x sample-reducing agent
(Life Technologies). Samples were then heated for 5 min at 95 ◦C, and 20 µg of protein was
loaded onto 4–12% gradient NuPAGE Bis-Tris Protein gels. Proteins were separated for
55 min at 200 V in an XCell sure-lock tank with 1x NuPAGE® MOPS SDS running buffer
(Life Technologies). The Western transfer was then performed using a Bio-Rad TurboBlot
in cold transfer buffer (25mM Tris-base, 75 mM Glycine, 10% Methanol, 0.1% SDS) and
a 0.45 µm Immobilon-P PVDF membrane (Merck Millipore, Cork/IRL). Proteins were
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transferred for 90 min at 20 V with a 100 mA cut-off. PVDF membranes were blocked in
5% milk powder in TBS + Tween 0.1% (TBST) for 1 h. Blots were rinsed three times and
washed for three times 5 min in TBST. Primary antibodies (1:2000) in TBST with 0.05%
sodium azide were incubated with the blots over-night at 4 ◦C. Antibodies were from
Santa Cruz Biotechnology, Heidelberg/DE: β-Actin sc-130656, GLUT2 sc-31826, Human
SGLT3 sc-134521, rabbit iNOS C-19 sc-649. Blots were rinsed three times and washed three
times for 5 min in TBST and blocked for 10 min. Anti-rabbit secondary antibody (sc-2004)
(1:2000) in blocking buffer and blots were incubated for 1 h at room temperature. Blots
were rinsed three times, washed three times for 10 min in TBST and incubated for 3 min
with ECL Prime (GE Healthcare, Little Chalfont, UK). Protein signal was visualised using a
SynGene G:BOX with the GeneSnap software, version 7.12 (Synaptics, Cambridge, UK)
and a 1–20 min exposure time.
After visualization, the Restore™ Western Blot Stripping Buffer was added to strip the
antibody membrane after incubation for 15 min at 37 ◦C. The membrane was washed twice
with PBST and blocked for 60 min again for further incubating β-actin-primary antibody
(Antibodies-online GmbH, Aachen, Germany), which was chosen to normalize the relative
density.
4.9. Nitric-Oxide Detection
Cell media was harvested at day 21 from Caco-2/TC7 cells; 0.5 mL was diluted
1:3 in reaction buffer and filtered using Millipore 10,000 MWCO filters (Fisher Scientific,
Leicestershire, UK) by centrifugation for 5 min with 14,000× g on an Eppendorf 5417R
centrifuge. Filtrate was harvested and nitric oxide determined using a total Nitric Oxide
detection kit following the supplied protocol (Enzo Lifesciences, Exeter, UK).
4.10. Lipids Analysis
Gas chromatography–mass spectrometry (GC) determination was performed to inves-
tigate the lipid composition of tongue, stomach, duodenum, jejunum and ileum samples.
Samples were prepared as followed: the tissue lipid extracts were dried under nitrogen
and reconstituted in 200 µL of toluene. Methanol (800 µL) was added to the lipid extract
in toluene and then acidified with 100 µL of acetyl chloride to effect transesterification.
Samples were incubated for 2 h at 60 ◦C, cooled and then neutralised with 3 mL of 6%
w/v aqueous sodium carbonate. The resulting mixture was then centrifuged for 10 min
at 2500× g at 40 ◦C to facilitate phase separation and the organic phase supernatant was
transferred to a vial for GC analysis. GC analysis involves injection of 1 µL of the fatty acid
methyl ester mixture into a gas chromatograph (Agilent Technologies 7890A) with the car-
rier gas flow (H2) set at 1 mL/min. Proportions of fatty acids as weight % were quantified
by expressing the areas under chromatographic peaks as a % of the total integrated area.
The proportion of oleic acid ethanolamide (OEA) and palmitoyl ethanolamide (PEA) in
sample tissues was determined using liquid chromatography–mass spectrometry.
4.11. Statistical Analysis
All data were shown in Microsoft Excel (2016). Gene expression levels were calculated
with the Livak 2-44CT method. Differences between two groups or among over three
groups were analysed using t-test and one-way ANOVA, respectively, using SPSS 24.0
software (Chicago, IL, USA). Significant differences in statistic were accepted if p < 0.05,
and highly significant differences in statistic were accepted if p < 0.01. All results are
presented as mean ± standard error of the mean (SEM).
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